. Author manuscript; available in PMC: 2010 Sep 28.

Published in final edited form as: Clin Infect Dis. 2009 Oct;49(7):1109–1116. doi: 10.1086/605594

Table 3.

Determinants of a first non-AIDS-defining malignancy, multivariate analyses including either cumulative exposure to viro-immunological markers or latest measurements (ANRS CO3 Aquitaine Cohort, 1998–2006; N = 4194; 144 cases)

Cumulative exposure^a,^b				Latest measurement^a,^b
Variables				Variables
Variables	HR	95% CI	p	Variables	HR	95% CI	p

CD4+ <500 cells/mm³ (per additional year of exposure)	1.13	[1.03 – 1.24]	0.01	CD4+ <500 cells/mm³ (yes vs no)	2.07	[1.41 – 3.05]	<0.001
Plasma HIV RNA >500 copies/mL (per additional year of exposure)	1.03	[0.94 – 1.13]	0.49	Plasma HIV RNA >500 copies/mL (yes vs no)	1.34	[0.94 – 1.91]	0.10
cART exposure (per additional year)	0.99	[0.91 – 1.08]	0.87	cART exposure (yes vs no)	1.04	[0.70 – 1.54]	0.85
Gender (women vs men)	0.59	[0.38 – 0.92]	0.02	Gender (w vs m)	0.60	[0.39 – 0.94]	0.02

NOTE.HR: Hazard Ratio for the association between a given variable and hazard of non-AIDS-defining malignancy

CI: Confidence Interval

Adjusted for other variables: CD4+ <500, plasma HIV RNA >500, cART exposure and gender

Akaike criterion (AIC) for cumulative exposure = 1725.4, AIC for latest measurement = 1717.8